21 February 2013 | News | By BioSpectrum Bureau
Nexus6 Smartinhaler allows physicians and patients to monitor real life use of inhaled treatments for respiratory conditions
Singapore: Auckland-based medical devices company Nexus6 has secured $4.6 million new investment to support international expansion of its Smartinhaler product range. The financial support is being led by international life sciences investment group BioScience Managers, which has contributed $1.6 million so far and is expected to provide upto $5 million. Nexus6 marks BioScience Managers' second investment from its Asia Pacific Healthcare Fund II.
The Smartinhaler range allows physicians and patients to monitor real life use of inhaled treatments for respiratory conditions. This means that physicians can remotely ensure that patients are adhering to the optimal treatment program for their condition. This new investment will enable Nexus6 to accelerate international expansion and significantly increase its sales and marketing capabilities.
Nexus6 founder Mr Garth Sutherland commented, "The combination of capital to execute our growth strategy and the experienced support of the BioScience Managers team provides us with a unique opportunity to take our company global. Smartinhaler represents a new paradigm in the management of asthma and respiratory diseases. We now have the resources to take this product to the world and continue to build Nexus6 into an international leader in remote patient monitoring solutions."
Bioscience Managers MD Mr Jeremy Curnock Cook, said that, "Nexus6 technology holds the key to not only ensuring better patient outcomes but also in minimising wastage and costs of treatment. It ensures patients with respiratory conditions take what they need and when they need it. In the current climate, technologies that enable remote monitoring of patients and support the delivery of better health outcomes, for less cost and with less wastage, are extremely important. Nexus6 also provides a unique supporting technology for respiratory clinical trials."
In support of the company's focus on international expansion, Nexus6 moves forward with a board of directors comprising Dr Doug Wilson, Mr Jeremy Curnock Cook, Mr Matt McNamara, Ms Maxine Simmons, and company founder Mr Garth Sutherland; bringing together a group that has significant global experience in the development, sales, marketing and management of biomedical companies.
The company offers its sincere thanks to the outgoing board members Mr David Bone, Dr David Evans, Dr Iain McCormick and Dr Dennis Row for their significant contributions and careful stewardship of the company, which has enabled Nexus6 to reach this stage in development. The company is grateful for the continued support of its existing shareholders K1W1, Ice Angels Nominees, Cure Kids Ventures, NZ Venture Investment Fund (SCIF) and individual investors.